ASH 2020: Results of a study examining Mosunetuzumab for first line treatment of unfit patients with DLBCL.
Home / Resource Library / Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma